This clinical trial focuses on myopia, also known as nearsightedness, a vision condition where distant objects appear blurry while close objects remain clear. The study examines two different concentrations of atropine eye drops (0.5% and 0.05%) to prevent the worsening of myopia in children. Atropine is a medication that has been used in eye care and is being studied for its ability to slow down the progression of nearsightedness.
The study aims to determine which concentration of the eye drops works better in European children who have progressive myopia. Children in the study will receive either the stronger (0.5%) or weaker (0.05%) version of the eye drops. The treatment will continue for several years to understand how well each concentration works in preventing the condition from getting worse.
During the study, doctors will monitor changes in children’s vision and eye health. They will also look at how safe the different concentrations are, how well children follow the treatment plan, and what happens after the treatment ends. The eye drops will be given daily, and regular check-ups will help track the children’s eye health throughout the study period.
The Netherlands 
